Literature DB >> 23018115

Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody.

Lubna Abuqayyas1, Joseph P Balthasar.   

Abstract

The current work examines the role of Fcγ-receptors on the elimination and tissue distribution of 8C2, a model murine IgG1 monoclonal antibody. The plasma pharmacokinetics of (125)Iodine-labeled 8C2 were investigated in C57BL/6 control mice, FcγRI/RIII knockout mice, and FcγRIIb knockout mice, following intravenous doses of 0.04, 0.1 and 0.4 mg/kg. Plasma samples were collected and radioactivity was counted. Concentration data were analyzed with a population pharmacokinetic model. Additionally, the tissue disposition of 8C2 was investigated using whole body autoradioluminography (WBAL) and via counting excised tissues. Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice. Strain was not a statistically significant predictor for any of the parameters of the population model. 8C2 plasma clearance, distribution clearance, and central compartment volume were 0.00543 L/days/kg, 0.0598 L/days/kg, and 0.057 L/kg. No substantial differences in 8C2 tissue uptake were identified by analysis of excised tissues or by WBAL. In conclusion, FcγR knockout is associated with only minor effects on the plasma and tissue disposition of 8C2, a model murine IgG1 mAb.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23018115     DOI: 10.1016/j.ijpharm.2012.09.042

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  14 in total

1.  Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Authors:  Yanguang Cao; Joseph P Balthasar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-31       Impact factor: 2.745

2.  Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment.

Authors:  John M Harrold; Anson K Abraham
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-12       Impact factor: 2.745

3.  The Impact of FcγRI Binding on Immuno-PET.

Authors:  Delphine Vivier; Sai Kiran Sharma; Pierre Adumeau; Cindy Rodriguez; Kimberly Fung; Brian M Zeglis
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

Review 4.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

5.  Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody.

Authors:  Weirong Wang; Jocelyn Leu; Rebecca Watson; Zhenhua Xu; Honghui Zhou
Journal:  AAPS J       Date:  2018-04-17       Impact factor: 4.009

Review 6.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

7.  Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.

Authors:  Jamie Campbell; Josquin Nys; Laura Eghobamien; E Suzanne Cohen; Matthew J Robinson; Matthew A Sleeman
Journal:  MAbs       Date:  2016-08-12       Impact factor: 5.857

8.  Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody.

Authors:  Lubna Abuqayyas; Xiaoyan Zhang; Joseph P Balthasar
Journal:  Int J Pharm       Date:  2013-01-28       Impact factor: 5.875

9.  The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.

Authors:  Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis
Journal:  Neurotherapeutics       Date:  2020-10-14       Impact factor: 7.620

Review 10.  Pharmacokinetics of Monoclonal Antibodies.

Authors:  Josiah T Ryman; Bernd Meibohm
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.